Seasonal Inactivated Influenza Vaccine
Sponsors
Johns Hopkins Bloomberg School of Public Health, Pfizer, BioNTech SE
Conditions
COVID-19HealthyPREVENTION OF INVASIVE PNEUMOCOCCAL DISEASERespiratory Syncytial VirusSARS-CoV-2 Infection
Phase 3
Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age
CompletedNCT05301322
Start: 2022-04-13End: 2022-10-12Updated: 2023-10-27
Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age
CompletedNCT05310084
Start: 2022-04-20End: 2022-10-05Updated: 2024-06-12
Phase 4
Immune and Hormone Response to Influenza Vaccine
CompletedNCT01978262
Start: 2013-10-31End: 2017-08-31Updated: 2018-12-27
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
CompletedNCT02124161
Start: 2014-09-30End: 2015-05-31Updated: 2016-07-01